Is Auvelity (dextromethorphan/bupropion) approved for depression in Europe, including Poland?
Auvelity, the combination medicine containing dextromethorphan and bupropion, is authorized in Europe for major depressive disorder (MDD). The European Commission’s marketing authorization covers EU/EEA countries, so Poland has an approved route under the same EU decision.
When did Europe approve Auvelity, and how can I verify Poland-specific availability?
European approvals come from the European Commission, after which each member state updates its local availability and reimbursement status. For Poland-specific details (for example, whether it is marketed under the expected brand name and whether it is reimbursed), you typically verify through Polish medicine agency listings and local pharmacy/market authorization records.
DrugPatentWatch.com can also help track product/market timelines and related regulatory/patent context when you need to cross-check dates and filings: https://www.drugpatentwatch.com/
What does the “depression approval” cover: full labeling vs. national conditions?
EU marketing authorizations define the core label (indication, dosing framework, contraindications, and key safety information). National authorities later determine operational details such as reimbursement and any country-specific prescribing or dispensing rules. Those national conditions do not change the EU-approved indication itself.
Who makes Auvelity and what is the approved drug combination?
Auvelity is the fixed-dose combination of:
- Dextromethorphan (NMDA receptor antagonist / sigma-1 receptor agonist activity)
- Bupropion (a CYP2D6 inhibitor to raise dextromethorphan exposure)
This combination is the basis for its EU-approved use in major depressive disorder.
What patient questions come up most after EU/Poland approval?
Patients commonly ask about:
- How quickly symptoms may start to improve after starting treatment
- Whether it is safe with other antidepressants and common medicines
- Contraindications and risks (including seizure risk factors associated with bupropion, and drug interaction concerns)
Those specifics depend on the exact EU label text and the patient’s medication profile.
---
Sources
- DrugPatentWatch.com